2 recruiting, 1 active not recruiting, 1 terminated, 1 unknown. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 2, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Nephrectomy: new trials by email Literature Review of Nephrectomy trials Research Report on Nephrectomy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 31 | 2026-08-28 | 2026-10-23 |
| NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma Pembrolizumab, Stereotactic Ablative Radiotherapy, Nephrectomy - Renal Cell Carcinoma, Clear Cell, Somatic | Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 20 | 2022-02-08 | 2024-05-16 |
| Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery Axitinib (VEGF-TKI), Cytoreductive Nephrectomy (CN), Metastasectomy (MET) - Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | University of California, San Francisco | 6 | 2021-02-09 | 2025-11-19 |
| Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma Sunitinib, Tumor biopsy, Nephrectomy - Renal Cell Carcinoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2010-10-01 | 2012-07-31 | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) Sunitinib, Nephrectomy - Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 50 | 2008-06-24 | 2026-06-12 |
Carcinoma, Renal Cell (6) · Clear-cell metastatic renal cell carcinoma (1) · Kidney Neoplasms (1)
City of Hope Medical Center (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Peter MacCallum Cancer Centre, Australia (1) · University of California, San Francisco (1)
United States (4) · Australia (1)
Adanma Anji Ayanambakkam Attanathi (1) · David Y Oh, MD, PhD (1) · Eric Jonasch, MD (1) · Fairooz Kabbinavar, M.D. (1) · Shankar Siva, A/Prof (1) · Wesley Yip (1)
P30CA033572 (1), UM1CA186689 (1)